XERS: Xeris Biopharma Quarterly Revenue Growth

Xeris Biopharma (XERS) - corporate logo

Xeris Biopharma monetizes injectable treatments for endocrine pathologies, including glucagon in pre-filled pens. The quarterly sales dynamics reflect a trend where the value of 44.60 indicates the development status. Business scaling is streamlined through the outsourcing of XeriJect production and royalties. Stability is supported by a loyal R&D staff and the active hiring of qualified medical sales representatives.

XERS Xeris Biopharma Inc Quarterly Revenue Increase (07/04/2022 - 11/20/2026)

Summary analytical data breakdowns for Xeris Biopharma Inc (XERS)

- stock price and consensus target price:
- cash and cash flow indicators:
Manufactured products of Xeris Biopharma Holdings, Inc.

Tier-one investors require this indicator to filter assets based on the stability of commercial demand and to exclude securities ahead of a market cooling phase. The percentage change in quarterly revenue measures the dynamics of actual transactions, confirming through sales volume the demand for Xeris Biopharma (XERS) innovative liquid drug formulations and their recognition within the medical community.